Sign in
Not yet taking people in DenmarkPhase 4

RSV vaccine with an immune booster, alone or with pneumococcal vaccine, in COPD

Tests an RSV vaccine's immune effects in people with COPD aged 60 and older.

Key facts

Who runs it
Nordsjaellands Hospital
Where
Hilleroed, DenmarkSee the site
Registry title
COPD-2VAX: Enhancing Protection Against Respiratory Infections Through AS01-Mediated Innate Immune Activation in High-Risk Patients
Status
Not yet recruiting
Phase
Phase 4
People taking part
60 people, planned
Started
1 Sept 2025
Expected to end
31 Dec 2027
Type of study
Interventional
Record updated
8 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 60 or older with COPD who need hospital outpatient care and had a PPV23 vaccine more than one year ago.

Age
60 years or older
Sex
Women and men can both join.
Disease stage
A COPD diagnosis confirmed by a lung specialist, needing care at the hospital outpatient clinic.
Earlier treatment
Must have had the PPV23 vaccine more than one year before joining. Must never have had any PCV or RSV vaccine.

Main reasons for not taking part

  • Weakened immune system, for example HIV, cancer chemotherapy or medicines that suppress the immune system
  • Any earlier PCV or RSV vaccine
  • Acute illness in the past 14 days, including COPD flare-ups and fever
  • Any other vaccine in the past four weeks
  • Allergy to an ingredient of the trial medicine

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • A confirmed COPD diagnosis by a respiratory medicine specialist requiring attention at the hospital's outpatient clinic
  • Age≥60 years
  • Previous PPV23 vaccination more than one year before inclusion
  • Volunteer agrees to participate in all aspects of the trial and has signed the informed consent

Who cannot take part

  • Receipt of any PCV or RSV vaccine at any time
  • Acute illness within the previous 14 days (including COPD exacerbations and fever)
  • Receipt of any other vaccine within the last four weeks
  • Allergens towards one of the ingredients in the trial medication
  • Immunocompromised status (primary, or secondary immunodeficiencies e.g., HIV, cancer therapy chemo, any medications that would suppress the immune system)
  • Previous illness with Gullain-Barré syndrome

Where in Denmark

  • Nordsjaellands HospitalHilleroed, DenmarkNot yet recruiting

About the trial

What the trial wants to find out

This study aims to evaluate the specific and non-specific effects of innate immune activation induced by the AS01-adjuvanted RSV vaccine in individuals at high risk for severe respiratory disease and insufficient vaccine response. Our specific objectives are: 1. To investigate whether the AS01-adjuvanted RSV vaccine induces potent mucosal and systemic innate responses in COPD patients aged ≥ 60 years. 2. To evaluate whether ipsi- and/or contralateral co-administration with PCV20 enhances the vaccine-specific adaptive immune response to pneumococcal antigens. 3. To assess non-specific effects of the AS01-adjuvanted RSV vaccine regarding a) the duration of innate enhancement that affects adaptive responses using a controlled delayed vaccine-coadministration model, b) mucosal protection against viral and bacterial respiratory pathogens, and c) sustained systemic control of viral replication in chronic or latent infections.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
COPD-2VAX: Enhancing Protection Against Respiratory Infections Through AS01-Mediated Innate Immune Activation in High-Risk Patients
Plain-language title
RSV vaccine with an immune booster, alone or with pneumococcal vaccine, in COPDGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
8 December 2025